Broadfin Capital’s Exact Sciences EXAS Stock Holding History

Broadfin Capital’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-261,400	Closed	-$15.6M	–	51
2018 Q2	$15.6M	Buy	+261,400	New	+$14.1M	2.46%	14

Other funds holding EXAS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital's EXAS Position: Q3 2018 in Review

Broadfin Capital sold out of Exact Sciences (EXAS) in Q3 2018, closing a stake of 261,400 shares — an estimated $15.6M sold.

Broadfin Capital first reported a position in EXAS in Q2 2018 and held it in 1 quarter. The position peaked at $15.6M in Q2 2018. 364 funds tracked by Wall St. Rank hold EXAS as of Q3 2018.

Broadfin Capital reported no remaining Exact Sciences position as of Q3 2018 after selling out during the quarter.
Broadfin Capital sold 261,400 Exact Sciences shares in Q3 2018, an estimated $15.6M.
Broadfin Capital first reported a position in Exact Sciences in Q2 2018 and held it in 1 quarter.
Broadfin Capital's Exact Sciences position peaked at $15.6M in Q2 2018.
364 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2018.

Based on Broadfin Capital's 13F filing for Q3 2018, filed 14 Nov 2018.